Renal Cell Carcinoma

In this video, Farshid Sadeghi, MD, discussed data for a study examining cabozantinib-resistant kidney cancer at American Urological Association Annual Meeting.

In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.

In this video, Farshid Sadeghi, MD, discussed data presented on renal cell carcinoma at American Urological Association Annual Meeting.

CHICAGO – Cabozantinib plus nivolumab showed promising efficacy in patients with papillary, unclassified or translocation-associated renal cell carcinoma, according to updated phase 2 study results presented at ASCO Annual Meeting.

In this video, Nour Abdallah, MD, discusses an abstract presented at American Urological Association Annual Meeting that investigated tumor contact surface area score and the potential use of artificial intelligence models in kidney cancer.

In this video, Nour Abdallah, MD, discusses an abstract from American Urological Association Annual Meeting on the use of artificial intelligence to predict the postoperative glomerular filtration rate after partial or radical nephrectomy.

In this video, Nour Abdallah, MD, discusses an abstract she presented at American Urological Association Annual Meeting, about artificial intelligence generation of the RENAL nephrometry score in the treatment of kidney cancer.

In this video, Nour Abdallah, MD, discusses an abstract examining the artificial intelligence-generated Centrality Index score presented at American Urological Association Annual Meeting.

CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results.

CHICAGO — The addition of CBM588 to immune checkpoint inhibitor-based therapy significantly increased PFS and response rates with no impact on stool microbiome diversity among a small cohort of patients with metastatic renal cell carcinoma.